Forbion
Investor profile
Venture capital
Also recorded as: Forbion Capital Partners · Forbion Ventures
Deals
33
distinct rounds
Companies
30
backed
Active span
2011–2026
16 yrs
Total round €
€2.5B
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- Jeito Capital5
- Sofinnova Partners5
- Novartis Venture Fund4
- Novo Holdings4
- BioGeneration Ventures3
- Gilde Healthcare3
- Polaris Partners3
- Wellington Partners3
- Atlas Venture2
- Boehringer Ingelheim Venture Fund2
- Brandon Capital2
- Corteva2
- Cowen Healthcare Investments2
- Edmond de Rothschild Venture Capital2
- Forbion Growth2
- GIMV2
- High-Tech Gründerfonds (HTGF)2
- Invus2
- NRW.BANK2
- Panakès Partners2
- Pontifax Funds2
- RA Capital Management2
- Sunstone Capital2
- UPMC Enterprises2
- Ysios Capital2
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Bicycle Therapeutics | UK | 1 | €513M |
| Verdiva Bio | UK | 1 | €399M |
| Azafaros | Netherlands | 2 | €157M |
| Noema Pharma | Switzerland | 2 | €135M |
| Anaveon | Switzerland | 1 | €106M |
| Tropic | UK | 1 | €91M |
| Orbis Medicines | Denmark | 1 | €90M |
| Citryll | Netherlands | 1 | €85M |
| Precirix | Belgium | 1 | €80M |
| Complement Therapeutics | Germany | 1 | €72M |
| Pheon Therapeutics | UK | 1 | €71M |
| Northsea Therapeutics | Netherlands | 1 | €71M |
| Mosanna Therapeutics | Switzerland | 1 | €70M |
| F2G | UK | 1 | €69M |
| Numab | Switzerland | 1 | €53M |
| Vectivbio | Switzerland | 1 | €53M |
| CatalYm | Germany | 1 | €50M |
| Inflazome | Ireland | 1 | €40M |
| Sanifit | Spain | 1 | €37M |
| CellNovo | UK | 1 | €36M |
| Enterprise Therapeutics | UK | 1 | €30M |
| Replimune | UK | 1 | €27M |
| Allecra Therapeutics | Germany | 1 | €22M |
| Rigontec | Germany | 2 | €18M |
| Eeden | Germany | 1 | €18M |
| Novameat | Spain | 1 | €17M |
| PACT | UK | 1 | €17M |
| OMEICOS | Germany | 1 | €17M |
| SOLASTA Bio | UK | 1 | €13M |
| Seamless Therapeutics | Germany | 1 | €12M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Bicycle Therapeutics | Other | €513M | 2024-05 |
| Verdiva Bio | Series A | €399M | 2025-01 |
| Azafaros | Series B | €132M | 2025-05 |
| Noema Pharma | Series B | €106M | 2023-03 |
| Anaveon | Series B | €106M | 2021-12 |
| Tropic | Series C | €91M | 2026-03 |
| Orbis Medicines | Series A | €90M | 2025-01 |
| Citryll | Series B | €85M | 2024-12 |
| Precirix | Series B | €80M | 2022-03 |
| Complement Therapeutics | Series A | €72M | 2023-04 |